Project Grant R44TR002572

Khloris Biosciences, Inc. received a $3.46 million Project Grant from the National Institutes of Health National Heart, Lung and Blood Institute to develop and validate a collection of induced pluripotent stem cell-derived cardiomyocyte cell lines. Under the Cardiovascular Diseases Research program (CFDA 93.837), Khloris will establish 50 cell lines from healthy individuals and patients with common hereditary cardiac disorders such as hypertrophic cardiomyopathy, dilated cardiomyopathy, and long...

This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...

This $900,804 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program supports the development and validation of an integrated microphysiological screening platform (MPS) with "virtual human" models to assess chemical toxicity and variability in human responses. The key objectives are to create an MPS platform that can elucidate inter-donor variabilities in mitochondrial toxicity and...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to develop feedback-controlled closed-loop manufacturing processes for differentiating human pluripotent stem cells into cardiomyocytes. The $590,283 award, made on February 1, 2025, will fund the University of Wisconsin-Madison's research to improve the robustness and reproducibility of this stem cell differentiation process....

This $500,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a novel human stem cell-based microfluidic developmental toxicology platform. The University of Michigan will receive funding from September 2022 to August 2024 to conduct technological development of a repeatable, controllable, high-throughput microfluidic system for generating three-dimensional multicellular organoid models for toxicity testing. The platform seeks...

This $1,000,000 National Science Foundation project grant supports research at the University of Wisconsin-Madison to develop single cell-level programming of human induced pluripotent stem cell differentiation into chamber-specific cardiomyocytes. The goal is to generate cardiomyocytes from each chamber of the heart through precise control of Wnt and retinoic acid signaling at the single cell level via engineered genetic programs and superstructures. If successful, this approach could establish...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $402,403 to Emory University to develop a high-throughput functional assessment platform using human cardiospheres to detect and mitigate chemotherapy-induced cardiotoxicity. The project aims to (1) establish a robust, automated system to assess calcium transients in 3D human cardiomyocyte models as an indicator of chemotherapy-induced cardiac adverse effects, and (2) evaluate novel...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will establish an innovative Organoid-AI system to accurately assess cardiotoxicity induced by Tyrosine Kinase Inhibitors (TKIs) used in cancer treatment. The $547,020 award, running from September 2024 to August 2025, will enable the University of North Texas to develop this next-generation preclinical model. Through the project's three...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...

This Cooperative Agreement awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $539,081 in funding to The Leland Stanford Junior University to elucidate sex differences in radiation-induced cardiotoxicity. The project aims to leverage a "Cell Village" strategy using human induced pluripotent stem cell (iPSC) derivatives from a diverse cohort of 200 individuals to study the complex interplay of...